常染色体显性阿尔茨海默病脑脊液中可溶性TREM2及其与其他生物标志物和认知的关联:一项纵向观察性研究
基于DIAN观察性研究,纳入常染色体显性阿尔茨海默病致病变异携带者155例和非携带者93例,纵向分析脑脊液可溶性TREM2与Aβ沉积、tau病理、神经影像及认知的关联。携带者基线脑脊液Aβ42低预示可溶性TREM2年增长加快,可溶性TREM2增长加快与Aβ沉积减慢、tau病理减缓、楔前叶皮层萎缩减轻及认知下降减慢相关。
要点
- 基线脑脊液Aβ42低是可溶性TREM2年增长加快的唯一预测因素。
- 症状前携带者中可溶性TREM2增长加快与Aβ42下降减慢相关(r=0.56)。
- 症状前携带者中可溶性TREM2增长加快与认知下降减慢相关(r=0.67)。
核心结论
- 在常染色体显性阿尔茨海默病中,TREM2反应位于Aβ聚集首次病理变化之后的淀粉样蛋白级联中。
- 可溶性TREM2对Aβ沉积、Aβ依赖的tau病理、皮层萎缩和认知下降可能具有有益作用。
- 可溶性TREM2可能是临床试验设计和解读的关键标志物。
研究设计与样本
- 对DIAN观察性研究数据的纵向分析,纳入有常染色体显性阿尔茨海默病家族史的18岁以上参与者。
- 2009年1月1日至2019年7月31日入组,致病变异携带者155例,非携带者93例。
- 无症状者(CDR=0)每2年、有症状者(CDR>0)每年采集脑脊液,用新型免疫分析法检测可溶性TREM2。
- 用经过验证的免疫分析法检测脑脊液Aβ40、Aβ42、t-tau和p-tau。
- 预设神经影像指标为PiB-PET总皮层摄取、MRI楔前叶皮层厚度和海马体积。
主要发现
- 携带者中,基线脑脊液Aβ42低(β=-4.28×10⁻²[SE 0.013],p=0.0012)是可溶性TREM2后续年增长加快的唯一预测因素,而PiB-PET高皮层摄取(β=-5.51×10⁻³[0.011],p=0.63)不是。
- 症状前携带者中,可溶性TREM2年增长加快与脑脊液Aβ42下降减慢相关(r=0.56[0.22],p=0.011)。
- 有症状携带者中,可溶性TREM2年增长加快与PiB-PET年增长减慢相关(r=-0.67[0.25],p=0.0060)。
- 症状前携带者中,可溶性TREM2年增长低于中位数者,脑脊液p-tau年增长与PiB-PET信号年增长相关(r=0.45[0.21],p=0.035),高于中位数者未观察到此相关。
- 症状前携带者中,可溶性TREM2年增长高于或低于中位数者,纵向评估时脑脊液Aβ42与PiB-PET摄取呈相反关联。
临床怎么用
- 可溶性TREM2可能是临床试验设计和解读的关键标志物。
- 增强TREM2的疗法正在研发中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic modulation of TREM2-dependent microglial function might provide an additional strategy to slow the progression of Alzheimer's disease. Although studies in animal models suggest that TREM2 is protective against Alzheimer's pathology, its effect on tau pathology and its potential beneficial role in people with Alzheimer's disease is still unclear. Our aim was to study associations between the dynamics of soluble TREM2, as a biomarker of TREM2 signalling, and amyloid β (Aβ) deposition, tau-related pathology, neuroimaging markers, and cognitive decline, during the progression of autosomal dominant Alzheimer's disease. METHODS: We did a longitudinal analysis of data from the Dominantly Inherited Alzheimer Network (DIAN) observational study, which includes families with a history of autosomal dominant Alzheimer's disease. Participants aged over 18 years who were enrolled in DIAN between Jan 1, 2009, and July 31, 2019, were categorised as either carriers of pathogenic variants in PSEN1, PSEN2, and APP genes (n=155) or non-carriers (n=93). We measured amounts of cleaved soluble TREM2 using a novel immunoassay in CSF samples obtained every 2 years from participants who were asymptomatic (Clinical Dementia Rating [CDR]=0) and annually for those who were symptomatic (CDR>0). CSF concentrations of Aβ40, Aβ42, total tau (t-tau), and tau phosphorylated on threonine 181 (p-tau) were measured by validated immunoassays. Predefined neuroimaging measurements were total cortical uptake of Pittsburgh compound B PET (PiB-PET), cortical thickness in the precuneus ascertained by MRI, and hippocampal volume determined by MRI. Cognition was measured using a validated cognitive composite (including DIAN word list test, logical memory delayed recall, digit symbol coding test [total score], and minimental status examination). We based our statistical analysis on univariate and bivariate linear mixed effects models. FINDINGS: In carriers of pathogenic variants, a high amyloid burden at baseline, represented by low CSF Aβ42 (β=-4·28 × 10-2 [SE 0·013], p=0·0012), but not high cortical uptake in PiB-PET (β=-5·51 × 10-3 [0·011], p=0·63), was the only predictor of an augmented annual rate of subsequent increase in soluble TREM2. Augmented annual rates of increase in soluble TREM2 were associated with a diminished rate of decrease in amyloid deposition, as measured by Aβ42 in CSF (r=0·56 [0·22], p=0·011), in presymptomatic carriers of pathogenic variants, and with diminished annual rate of increase in PiB-PET (r=-0·67 [0·25], p=0·0060) in symptomatic carriers of pathogenic variants. Presymptomatic carriers of pathogenic variants with annual rates of increase in soluble TREM2 lower than the median showed a correlation between enhanced annual rates of increase in p-tau in CSF and augmented annual rates of increase in PiB-PET signal (r=0·45 [0·21], p=0·035), that was not observed in those with rates of increase in soluble TREM2 higher than the median. Furthermore, presymptomatic carriers of pathogenic variants with rates of increase in soluble TREM2 above or below the median had opposite associations between Aβ42 in CSF and PiB-PET uptake when assessed longitudinally. Augmented annual rates of increase in soluble TREM2 in presymptomatic carriers of pathogenic variants correlated with decreased cortical shrinkage in the precuneus (r=0·46 [0·22]), p=0·040) and diminished cognitive decline (r=0·67 [0·22], p=0·0020). INTERPRETATION: Our findings in autosomal dominant Alzheimer's disease position the TREM2 response within the amyloid cascade immediately after the first pathological changes in Aβ aggregation and further support the role of TREM2 on Aβ plaque deposition and compaction. Furthermore, these findings underpin a beneficial effect of TREM2 on Aβ deposition, Aβ-dependent tau pathology, cortical shrinkage, and cognitive decline. Soluble TREM2 could, therefore, be a key marker for clinical trial design and interpretation. Efforts to develop TREM2-boosting therapies are ongoing. FUNDING: German Research Foundation, US National Institutes of Health.
引用
- Morenas-Rodríguez E, Li Y, Nuscher B, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurol. 2022. PMID: 35305339. doi:10.1016/S1474-4422(22)00027-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。